Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06169319 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
NCT06169319: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT06169319 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 231 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06169319, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
Study Summary
This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Collagenase Clostridium Histolyticum (CCH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 2 |
What the finished NCT06169319 record still lists
NCT06169319 is an interventional study that assigns participants to a tested intervention. The registered 231 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06169319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06169319 about?
NCT06169319 is a clinical study titled "A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)". This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.
What is the current status of trial NCT06169319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2024-01-03. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT06169319?
The interventions under investigation include: Placebo (BIOLOGICAL), Collagenase Clostridium Histolyticum (CCH) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06169319?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06169319's enrollment target sits among peer trials
231 257th of 2000 higher than 1,744 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04077099 · 231 participants · Phase 1
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
- NCT05019495 · 231 participants · NA
Optimizing Tobacco Treatment Delivery for People Living With HIV
- NCT06023589 · 231 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- NCT06734351 · 231 participants · Phase 3
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI